dulanermin (AMG 951) News

|||||||||| dulanermin (AMG 951) / Amgen, Roche
Journal: Aminopeptidase N Inhibitors as Pointers for Overcoming Antitumor Treatment Resistance. (Pubmed Central) - Sep 18, 2022
Recently, APN inhibition has been shown to augment DR4-induced tumor cell death and thus overcome resistance to cancer treatment with DR4-ligand TRAIL, which is available as a recombinant soluble form dulanermin...In addition, a selective anti-proliferative activity against cancer cells expressing APN was demonstrated. Our semicarbazones and thiosemicarbazones are the first compounds of these structural types of Schiff bases that were reported to inhibit not only a zinc-dependent aminopeptidase of the M1 family but also a metalloenzyme.

|||||||||| mapatumumab (HGS-ETR1) / GSK, dulanermin (AMG 951) / Amgen, Roche
Clinical, Review, Journal: The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials. (Pubmed Central) - Apr 2, 2021
We have also aimed to introduce all novel approaches of TRAIL utilization in cancer treatment and discussed the most promising drugs which are likely to enter clinical trials in humans. To date, different strategies were introduced in order to activate anti-tumor immune responses with the aim of achieving the highest efficacy and minimal toxicity.In this review, we discuss the most promising TRAIL-based clinical trials and their therapeutic strategies.

||||||||||  dulanermin (AMG 951) / Amgen, Roche
New P3 trial, Metastases:  A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection (clinicaltrials.gov) -  Mar 19, 2017
P3, N=417, Active, not recruiting,  Sponsor: Shanghai Gebaide Biotechnology Co., Ltd.

||||||||||  dulanermin (AMG 951) / Amgen, Roche
Trial initiation date:  A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab (clinicaltrials.gov) -  Jun 15, 2016
P2, N=213, Completed,  Sponsor: Amgen
To date, different strategies were introduced in order to activate anti-tumor immune responses with the aim of achieving the highest efficacy and minimal toxicity.In this review, we discuss the most promising TRAIL-based clinical trials and their therapeutic strategies. Initiation date: Nov 2007 --> Jun 2006

||||||||||  Avastin (bevacizumab) / Roche, dulanermin (AMG 951) / Amgen, Roche
Trial completion, Combination therapy, Metastases:  A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer (clinicaltrials.gov) -  Apr 13, 2014
P1, N=23, Completed,  Sponsor: Genentech
Initiation date: Nov 2007 --> Jun 2006 Active, not recruiting --> Completed

||||||||||  Avastin (bevacizumab) / Roche, dulanermin (AMG 951) / Amgen, Roche
Trial completion, Combination therapy, Metastases:  A Study of Dulanermin Administered in Combination With Camptosar (clinicaltrials.gov) -  Sep 8, 2013
P1, N=42, Completed,  Sponsor: Genentech
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  dulanermin (AMG 951) / Amgen, Roche
Trial completion:  A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab (clinicaltrials.gov) -  Oct 28, 2012
P2, N=213, Completed,  Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Rituxan (rituximab) / Roche, dulanermin (AMG 951) / Amgen, Roche
Trial termination, Combination therapy:  A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas (clinicaltrials.gov) -  Nov 21, 2011
P1/2, N=72, Terminated,  Sponsor: Genentech
Active, not recruiting --> Completed Completed --> Terminated



	Diseases Companies Products Productz Mechanisms of Action Sites